Clinical Trial Update: Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid [NA]

View source ↗

Summary

A terminated clinical trial investigated nicotinic acid for managing inflammation and atherosclerosis in dialysis patients, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Disease
• End-stage Renal Disease

Drugs mentioned

• Nicotinic acid (niacin)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Dialysis, Cardiovascular Disease | NA | Status: TERMINATED | Results posted: 2017-06-28